Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05314387

S-11 SMR TT Hybrid Glenoid and Cementless Finned Short Stem

Post-market, prospective, non randomized, open label, multicentre, clinical study analysing outcomes of shoulder arthroplasty with SMR TT Hybrid Glenoid with or without SMR Cementless Finned Short Stem

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Key)

  • Both genders;
  • Age ≥ 18 years old;
  • Full skeletal maturity;
  • Life expectancy over 5 years;
  • Patient is requiring primary unilateral arthroplasty based on physical examination and medical history;
  • Good bone quality evaluated by the Investigator and the intraoperative evaluation;
  • A diagnosis in the target shoulder of one or more of the S-11 SMR TT Hybrid Glenoid and Cementless Finned Short Stem Version Sep 2021 2.0 Confidential Page11 following:
  • Primary osteoarthritis;
  • Secondary osteoarthritis;
  • Post-traumatic arthritis;
  • Rheumatoid arthritis;
  • Avascular necrosis
  • acute fractures of the humeral head that cannot be treated with other fracture fixation methods;
  • cuff tear arthropathy (only in combination with CTA Heads);
  • Glenoid arthrosis without excessive glenoid bone loss: A1, A2 and B1 according to Walch classification.

Exclusion criteria

(Key):

  • Patient requiring revision shoulder arthroplasty;
  • Osteoporosis with a history of non-traumatic fractures;
  • Steroid injections within the previous 3 months;
  • Contralateral shoulder replacement within the previous 3 months;
  • Significant proven or suspicious infection of the target shoulder or any serious infectious disease before the study according to the Investigator;
  • Significant neurological or musculoskeletal disorders that may compromise functional recovery;
  • Not recovered axillary nerve palsy;
  • Non functioning deltoid muscle;
  • Known or suspicious hypersensitivity to the metal or other components and materials of the implant;
  • Participation in any experimental drug/device study within the 6 months prior to the preoperative visit;
  • Women of childbearing potential who are pregnant, nursing, or planning to become pregnant.

These are key eligibility criteria, other eligibility criteria apply.

Treatment and study plan

SMR TT Hybrid Glenoid without Cementless Finned Short Stem

Device

The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.

SMR TT Hybrid Glenoid with Cementless Finned Short Stem

Device

The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.

The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation.

Primary outcomes

  1. Proportion of patients reaching a clinical progression from baseline to 24-month follow-up

    Time frame: 24 Months

    The primary endpoint consists of the proportion of patients reaching a clinical progression from baseline to 24-month follow-up measured as:

    • Constant score improvement of greater than 10;
    • Adjusted Constant score greater than or equal to 54.

Secondary outcomes

  1. Measure American Shoulder and Elbow Surgeons Shoulder Score (ASES)

    Time frame: Baseline to 24 and 60 Months

    The ASES questionnaire is composed of both a physician-rated component and a patient-reported component. The patient questions focus on joint pain, instability, and activities of daily living. Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.

  2. Measure Oxford shoulder score

    Time frame: Baseline to 24 and 60 Months

    Oxford Shoulder Score (OSS) is a 12-item patient-reported PRO specifically designed and developed for assessing outcomes of shoulder surgery.

  3. Measure Constant Score

    Time frame: Baseline to 24 and 60 Months

    The Constant-Murley score (CMS) is a 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient. The higher the score, the higher the quality of the function.

  4. Measure Simple Shoulder Test

    Time frame: Baseline to 24 and 60 Months

    Simple Shoulder Test (SST) is a series of 12 "yes" or "no" questions the patient answers about the function of the involved shoulder. The answers to these questions provides a standardized way of recording the function of a shoulder before and after treatment. The difference between the shoulder function before treatment and after the recovery period is the effectiveness of the treatment.

  5. Measure Patient Satisfaction

    Time frame: Baseline to 24 and 60 Months

    The satisfaction of the patients with regard to the effectiveness of the prosthetic treatment is graded on a scale from 1 to 5

  6. Stability of the SMR TT hybrid glenoid component with or without SMR cementless finned short stem

    Time frame: Immediately postoperative to 24 Months

    Rate of symptomatic radiolucent lines, loosening and subsidence ≥2 mm

  7. System conversion rate, intended as a conversion within the SMR system from anatomic to reverse

    Time frame: 24 Months

    The SMR shoulder system is a modular system and in case of evolution of the pathology it may be easily converted from one configuration to another.

  8. Failure rate, intended as removal of the SMR TT hybrid glenoid component

    Time frame: Immediately postoperative to 24 Months

    A removal of the glenoid component is intended as a revision and a failure of the implant.

  9. Failure rate, intended as removal of the SMR cementless finned short stem

    Time frame: Immediately postoperative to 24 Months

    A removal of the stem component is intended as a revision and a failure of the implant.

  10. Incidence of device-related AE/SAE (ADE/SADE)

    Time frame: Immediately postoperative to 24 and 60 Months

    Device Related Adverse Events/Serious Adverse Events, device deficiencies, malfunctions and use errors at all follow-up time points

  11. Survival rate (Kaplan-Meier)

    Time frame: 60 Months

Study contacts

Contact information is provided by the study sponsor or research team.

Laura Sanchez

CONTACT

[email protected]

817-233-1686

Ryan Bacchus

CONTACT

[email protected]

817-233-1686

Sponsors and collaborators

Lead sponsor

Limacorporate S.p.a

Industry

Registry information

Official study title

A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty With SMR TT Hybrid Glenoid With or Without SMR Cementless Finned Short Stem

Important dates

Study start
2022
Primary completion
2027
Study completion
2029
First posted
Apr 6, 2022
Registry last updated
Apr 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.